Gina Mauro

home / authors / gina-mauro

Articles

Treatment for Relapsed/Refractory Multiple Myeloma Shows Promising Clinical Activity, Safety

Gina Mauro

March 9th 2021

Teclistamab showed promising clinical activity and a tolerable safety profile in patients with relapsed/refractory multiple myeloma.

Zanidatamab Gets FDA Breakthrough Designation for HER2 Gene–Amplified Biliary Tract Cancer

Gina Mauro

December 1st 2020

The FDA has granted a breakthrough therapy designation to zanidatamab for the treatment of patients with HER2 gene–amplified biliary tract cancer who have received prior therapy.

FDA Approves FoundationOne CDx Genomic Test as Companion Diagnostic for Larotrectinib

Gina Mauro

October 26th 2020

The FDA has approved the FoundationOne CDx (F1CDx) comprehensive genomic test as a companion diagnostic for larotrectinib (Vitrakvi) to identify patients with NTRK1/2/3 gene fusions across all solid tumors.

FDA Fast Tracks Combination Therapy for Chronic Lymphocytic Leukemia

Gina Mauro

October 22nd 2020

The FDA granted fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the treatment of chronic lymphocytic leukemia.

Published: October 23rd 2024 | Updated: October 24th 2024

What to Know About E Coli Outbreak Linked to McDonald’s Quarter Pounders